FDA OKs priority review for Abilify to treat depression

07/17/2007 | Forbes

Bristol-Myers Squibb says the agency granted its request to speed the approval review process for Abilify as a treatment to combat major depression in adults. Bristol-Myers, in co-promotion with Japan's Otsuka Pharmaceutical Co., currently markets the drug for treatment of bipolar disorder and schizophrenia.

View Full Article in:

Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park